A review of current clinical findings with fluvastatin

被引:17
作者
Garnett, WR
机构
[1] Virginia Commonwealth University Medical College, Richmond
关键词
D O I
10.1016/S0002-9149(96)00658-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fluvastatin, the newest member of the class of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors, is structurally different from the fungal metabolites (lovastatin, pravastatin, and simvastatin) and is wholly synthetic. Fluvastatin has a distinct biopharmaceutical profile, including a short systemic exposure time (half-life of 1.2 hours) and virtually no active circulating metabolites. Fluvastatin is targeted to the liver, where it is rapidly metabolized; 98% of fluvastatin is protein bound. Double-blind, placebo-controlled studies have demonstrated that fluvastatin at daily dosages of 20-40 mg produces significant decreases from baseline in low-density lipoprotein (LDL) cholesterol on the order of 22-31% in patients with severe primary hypercholesterolemia (mean baseline LDL cholesterol 227 mg/dL) and decreases of 19-25% in patients with familial hypercholesterolemia (mean baseline LDL cholesterol 270 mg/dL). Interim results of a titrate-to-goal, 20-week study in patients with moderate hypercholesterolemia (LDL cholesterol greater than or equal to 160 mg/dL and triglycerides less than or equal to 350 mg/dL) demonstrate that fluvastatin, 20 mg/day, lowers LDL cholesterol by 21% within 6 weeks. Long-term results indicate that the lipid-lowering effects of fluvastatin are sustained for 96 weeks. Further, 1 study has shown that the combination of low-dose fluvastatin plus niacin decreased LDL cholesterol levels 40% without untoward adverse events, suggesting that this combination is effective and safe for patients needing intensive lipid-lowering therapy. Asymptomatic, reversible increases in hepatic transaminase levels occur in fluvastatin-treated patients at a frequency comparable to that reported for other HMG-CoA reductase inhibitors. The 20-30% reduction in LDL cholesterol required by the majority of patients with hypercholesterolemia can be achieved with fluvastatin at 20 or 40 mg/day as well as with the other available HMG-CoA reductase inhibitors at their most commonly prescribed doses. Fluvastatin, priced 40% lower than other statins, provides the most cost-effective means of safely achieving goal LDL cholesterol levels in these patients.
引用
收藏
页码:20 / 25
页数:6
相关论文
共 18 条
[1]  
[Anonymous], 1993, Arch Intern Med, V153, P1321
[2]   COMPARISON OF PROPERTIES OF 4 INHIBITORS OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE [J].
BLUM, CB .
AMERICAN JOURNAL OF CARDIOLOGY, 1994, 73 (14) :D3-D11
[3]   EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA [J].
BRADFORD, RH ;
SHEAR, CL ;
CHREMOS, AN ;
DUJOVNE, C ;
DOWNTON, M ;
FRANKLIN, FA ;
GOULD, AL ;
HESNEY, M ;
HIGGINS, J ;
HURLEY, DP ;
LANGENDORFER, A ;
NASH, DT ;
POOL, JL ;
SCHNAPER, H .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) :43-49
[4]   FLUVASTATIN LONG-TERM EXTENSION TRIAL (FLUENT) - SUMMARY OF EFFICACY AND SAFETY [J].
DAVIDSON, MH .
AMERICAN JOURNAL OF MEDICINE, 1994, 96 :S41-S44
[5]   COMPARATIVE EFFECTS OF LOVASTATIN AND NIACIN IN PRIMARY HYPERCHOLESTEROLEMIA - A PROSPECTIVE TRIAL [J].
ILLINGWOUTH, DR ;
STEIN, EA ;
MITCHEL, YB ;
DUJOVNE, CA ;
FROST, PH ;
KNOPP, RH ;
TUN, P ;
ZUPKIS, RV ;
GREGUSKI, RA .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (14) :1586-1595
[6]   FLUVASTATIN WITH AND WITHOUT NIACIN FOR HYPERCHOLESTEROLEMIA [J].
JACOBSON, TA ;
CHIN, MM ;
FROMELL, GJ ;
JOKUBAITIS, LA ;
AMOROSA, LF .
AMERICAN JOURNAL OF CARDIOLOGY, 1994, 74 (02) :149-154
[7]  
LEVY RI, 1993, CIRCULATION, V87, P45
[8]  
MARCUS A, 1994, CLIN CARDIOL, V17, P16
[9]  
*MED EC CO, 1996, RED BOOK UPD
[10]  
OHTAWA M, 1989, RINSHO IYAKU, V5, P1123